Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy
暂无分享,去创建一个
Manousos E. Kambouris | Vita Dolzan | Alessio Squassina | Domenica Taruscio | Effy Vayena | Athanassios Vozikis | Christina Mitropoulou | Federico Innocenti | David N. Cooper | Barbara Prainsack | George P. Patrinos | Angela Brand | Paolo Fortina | Marc S. Williams | A. Brand | M. Lee | D. Cooper | D. Taruscio | E. Vayena | P. Fortina | F. Innocenti | B. Prainsack | G. Patrinos | F. Al-Mulla | R. V. van Schaik | Lada Leyens | A. Vozikis | A. Squassina | C. Mitropoulou | V. Dolžan | Fahd Al-Mulla | Ming Ta Michael Lee | Lada Leyens | Milan Macek Jr | Ron H. van Schaik | M. Macek Jr | M. Kambouris | M. Macek Jr.
[1] C. Pui,et al. Pharmacogenomics and Individualized Medicine: Translating Science Into Practice , 2012, Clinical pharmacology and therapeutics.
[2] Georges Magonette,et al. The Joint Research Centre of the European Commission , 2002 .
[3] D. Cooper,et al. Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. , 2014, Personalized medicine.
[4] Sarah Berwouts,et al. Approaches to quality management and accreditation in a genetic testing laboratory , 2010, European Journal of Human Genetics.
[5] Sarah Berwouts,et al. Quality assurance practices in Europe: a survey of molecular genetic testing laboratories , 2012, European Journal of Human Genetics.
[6] Marc S. Williams,et al. The Public Health Genomics Translation Gap: What We Don’t Have and Why It Matters , 2012, Public Health Genomics.
[7] Steve Olson,et al. Applying an Implementation Science Approach to Genomic Medicine: Workshop Summary , 2016 .
[8] Personhood and solidarity: what kind of personalized medicine do we want? , 2014, Personalized medicine.
[9] Michael S Watson,et al. Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine. , 2015, JAMA.
[10] Kostas Kampourakis,et al. Key challenges for next‐generation pharmacogenomics , 2014, EMBO reports.
[11] Athanassios Vozikis,et al. Stakeholder Analysis in Pharmacogenomics and Genomic Medicine in Greece , 2014, Public Health Genomics.
[12] Marc S. Williams. Can Genomics Deliver on the Promise of Improved Outcomes and Reduced Costs? , 2003 .
[13] D. Cooper,et al. A critical view of the general public's awareness and physicians' opinion of the trends and potential pitfalls of genetic testing in Greece. , 2011, Personalized medicine.
[14] George P Patrinos,et al. Economic Evaluation of Pharmacogenomics: A Value-Based Approach to Pragmatic Decision Making in the Face of Complexity , 2014, Public Health Genomics.
[15] G. Patrinos,et al. Nutrigenomics: A controversy , 2015, Applied & translational genomics.
[16] Jean-Christophe Nebel,et al. Meta-Analysis of Genes in Commercially Available Nutrigenomic Tests Denotes Lack of Association with Dietary Intake and Nutrient-Related Pathologies. , 2015, Omics : a journal of integrative biology.
[17] Thomas A. C. Reydon,et al. Genetics, genomics and society: the responsibilities of scientists for science communication and education. , 2012, Personalized medicine.
[18] George P Patrinos,et al. Pharmacogenomics and public health: implementing 'populationalized' medicine. , 2012, Pharmacogenomics.
[19] Welfare Administrative Costs. OFFICE OF INSPECTOR GENERAL , 1997 .
[20] Mara G. Aspinall,et al. The business value and cost-effectiveness of genomic medicine. , 2012, Personalized medicine.
[21] J. Ashton-Chess,et al. Market access challenges in the EU for high medical value diagnostic tests. , 2011, Personalized medicine.
[22] Edd Fleming,et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise , 2009, Nature Reviews Drug Discovery.
[23] Patrick Kierkegaard,et al. E-Prescription across Europe , 2013 .
[24] A. Coulter,et al. European patients' views on the responsiveness of health systems and healthcare providers. , 2005, European journal of public health.
[25] Darrol J. Baker,et al. Genetic tests obtainable through pharmacies: the good, the bad, and the ugly , 2013, Human Genomics.
[26] Insurance coverage for pharmacogenomic testing in the USA. , 2007, Personalized medicine.
[27] Christopher A. Macisco. The Office of Inspector General (OIG) , 2004 .
[28] Gert Matthijs,et al. The EuroGentest Clinical Utility Gene Cards continued , 2013, European Journal of Human Genetics.